SKSagar Kansara

Sagar Kansara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sagar Kansara has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Current Evidence of Precision Medicine via Multi‐Omic Approaches in Head and Neck Squamous Cell Carcinoma

    by Ethan R. Leoni, Ethan D. Abbenante, Kevin J. Contrera, Karishma Chhabria Unrue, Alexander N. Hanania, Sagar G. Kansara

    Background: Perioperative and adjuvant immunotherapy are new standards of care for selected patients with resectable locoregionally advanced HPV‐negative HNSCC, but low pathologic response rates and a lack of predictive biomarkers limit patient selection and response‐adapted care. This review examines multi‐omic approaches to predicting immunotherapy response and personalizing therapy. Methods: A narrative review of current multi‐omic strategies for HNSCC was performed. Data providing predictive, prognostic, diagnostic, surveillance, or exploratory value was summarized. Results: Multi‐omics may identify those likely to benefit from immunotherapy. Single‐cell transcriptomics reveals changes in the tumor immune microenvironment while spatial proteomics reveals tertiary lymphoid structures, dendritic cell networks, and protein signatures predicting immunotherapy response. Obstacles include unstandardized protocols, limited prospective validation, and small sample sizes. Conclusions: Multi‐omics can reshape biomarker‐driven HNSCC care, but implementation requires prospective validation, standardized protocols, and multi‐platform integration.

  • Open Access

    Measurement Tools for Radiation‐Induced Fibrosis in Head and Neck Cancer: A Systematic Review

    by Vanessa Helou, Pooja D. Reddy, Purva H. Rumde, Mary L. Klem, Sagar G. Kansara, Oldrich Virag, Yvonne M. Mowery, Nicole N. Scheff, Matthew E. Spector, Shaum Sridharan, et al.

    Background: Radiation‐induced fibrosis is a common, often debilitating late effect of head and neck cancer (HNC) treatment. An updated systematic review is needed to evaluate the reliability, validity, and clinical utility of fibrosis measurement tools. Methods: Cochrane Library, Medline, Embase.com , and Web of Science were systematically searched. Articles were independently screened by two reviewers using COSMIN checklists for risk of bias assessment, following PRISMA guidelines. Results: Of 4678 articles, 17 studies describing 13 tools met inclusion: six studies assessed four patient‐reported outcome measures, two assessed two clinician‐reported tools, and nine assessed seven imaging modalities. The Neck Fibrosis Scale, HN‐LEF Symptom Inventory, and LENT‐SOMA demonstrated validity and reliability. Young's modulus was the only imaging tool demonstrating both. Imaging studies had a higher risk of bias. Conclusion: Several subjective tools are reliable and valid for radiation‐induced fibrosis assessment in HNC. Young's modulus is the only objective imaging‐based tool that provides evidence of both validity and reliability, though methodological limitations remain.

  • Open Access

    Artificial Intelligence in Head and Neck Cancer: Towards Precision Medicine

    by Jacob Hagen, Logan Hornung, William Barham, Supratik Mukhopadhyay, Adam Bess, Kevin Contrera, Devraj Basu, Vlad Sandulache, Guillaume Spielmann, Sagar Kansara

    Head and neck cancer (HNC) encompasses malignant neoplasms originating from the soft tissues of the nasal cavity, paranasal sinuses, oral cavity, pharynx, larynx, skin, and thyroid


  • Open Access

    Recurrent and Metastatic Head and Neck Cancer: Mechanisms of Treatment Failure, Treatment Paradigms, and New Horizons

    by William T. Barham, Marshall Patrick Stagg, Rula Mualla, Michael DiLeo, Sagar Kansara

    Background: Head and neck cancer is a deadly disease with over 500,000 cases annually worldwide. Metastatic head and neck cancer accounts for a large proportion of the mortality associated with this disease. Many advances have been made in our understanding of the mechanisms of metastasis. The application of immunotherapy to locally recurrent or metastatic head and neck cancer has not only improved oncologic outcomes but has also provided valuable insights into the mechanisms of immune evasion and ultimately treatment failure. Objectives: This review paper will review our current understanding of biological mechanisms of treatment failure and metastasis. Published and ongoing clinical trials in the management of metastatic head and neck cancer will also be summarized. Methods: A narrative review was conducted to address the current understanding of the mechanisms of treatment failure and current treatment paradigms in recurrent and metastatic head and neck carcinoma. Conclusions: Our understanding of treatment failure in this disease is rapidly evolving. Immunotherapy represents a valuable new tool in the fight against recurrent and metastatic head and neck squamous cell carcinoma. Integrating patient and tumor specific data via artificial intelligence and deep learning will allow for a precision oncology approach, thereby achieving better prognostication and management of patients with this deadly disease.


  • Open Access

    Imaging of extranodal lymphomas in the head and neck: A case series and review of the literature

    by Chad Pierre Issa, Amberly Nunez, Rula Mualla, Sagar Kansara

    Extranodal lymphomas (ENLs) are relatively rare malignancies of the head and neck. Clinical presentation varies greatly depending on location, pattern of nodal involvement, and histologic subtype. The most frequently involved sites include the palatine tonsils and nasal cavity/paranasal sinuses, and over half of patients have concurrent nodal disease. Most are non-Hodgkin’s lymphomas of B-cell lineage. While the clinical presentation may mimic other pathologies of the head and neck, various radiographic features and patterns may help raise suspicion for ENL as a differential consideration. This is of critical importance given that the management and treatment of lymphomas differ significantly from other pathologies of the head and neck. In this case series, three cases of ENL in the head and neck are described, with an emphasis on radiographic findings. A review of epidemiology and treatment paradigms is also provided.


  • A prospective evaluation of neck and shoulder function following treatments of early‐stage human papillomavirus‐associated oropharynx cancer

    by Arushi Gulati, Karolina Plonowska‐Hirschfeld, Erika M. Stephens, Sagar Kansara, Aaron L. Zebolsky, Edgar Ochoa, Mary J. Xu, Patrick K. Ha, Chase M. Heaton, Sue S. Yom, et al.

    Objectives: To compare post‐treatment neck and shoulder function between human papillomavirus‐associated oropharynx squamous cell carcinoma (HPV + OPSCC) treatments.Design: Prospective, repeated‐measures study.Setting: Tertiary care center.Participants: Treatment‐naïve patients with American Joint Committee on Cancer eighth edition stage T0‐3/N0‐2 HPV+OPSCC.Main Outcome Measures: Patients completed the Neck Dissection Impairment Index (NDII) pre‐treatment and 3‐months and 1‐year post‐treatment. The NDII assesses 10 neck and shoulder functions scored 0–5 (total score 0–100), with higher scores suggesting better function.Results: A total of 106 patients underwent: surgery alone (SA, n = 46, 43%), surgery with adjuvant radiation ± chemotherapy (S + a[C]XRT, n = 18, 17%), or definitive radiation ± chemotherapy (d[C]XRT, n = 42, 40%). cTN classification and pre‐treatment NDII scores did not differ between groups. SA patients reported worsened 3‐month post‐treatment versus pre‐treatment self‐care (4.6 vs. 5.0), lifting light (4.6 vs. 5.0) and heavy (4.2 vs. 4.8) objects, overhead reach (4.5 vs. 4.9), activity (4.5 vs. 4.9), socialization (4.7 vs. 4.9), recreation (4.6 vs. 4.9), and overall score (86.8 vs. 95.3) (all p < 0.05). One‐year post‐treatment scores (n = 34) were no different than pre‐treatment in all domains. S + a[C]XRT patients reported worsened 3‐month versus pre‐treatment stiffness (4.0 vs. 4.8), lifting heavy objects (3.8 vs. 4.9), overhead reach (4.2 vs. 4.9), socialization (4.6 vs. 5.0), recreation (4.4 vs. 4.9) and overall score (82.4 vs. 96.0) (all p < 0.05). One‐year post‐treatment scores (n = 13) were no different than pre‐treatment in all domains. d[C]XRT patients reported worsened 3‐month versus pre‐treatment difficulty lifting heavy objects (4.3 vs. 4.7) and recreation (4.3 vs. 4.7). One‐year posttreatment scores (n = 21) were no different than pre‐treatment in all domains.Conclusion: HPV + OPSCC patients may experience mild shoulder/neck dysfunction 3 months after treatment that usually resolves by 1 year, independent of treatment modality.